Multifunctional, CD44v6-Targeted ORMOSIL Nanoparticles Enhance Drugs Toxicity in Cancer Cells

Area of Science:

• Nanotechnology
• Materials Science
• Biomedical Engineering

Background:

• Organic-modified silica (ORMOSIL) nanoparticles offer potential as drug delivery systems.
• Targeting cancer stem cells (CSCs) is crucial for effective cancer therapy.
• CD44v6 receptor is a marker overexpressed on certain cancer stem cells.

Purpose of the Study:

• To develop and evaluate PEGylated ORMOSIL nanoparticles as targeted nanovectors for cancer therapy.
• To conjugate anti-CD44v6 antibody and hyaluronic acid (HA) to ORMOSIL nanoparticles for CSC targeting.
• To assess the efficacy of targeted nanoparticles in delivering an anticancer drug and enhancing cytotoxicity.

Main Methods:

• ORMOSIL nanoparticles were synthesized using microemulsion condensation of vinyltriethoxysilane (VTES).
• Amine-functionalized nanoparticles were conjugated with anti-CD44v6 antibody and HA via thiol-maleimide and amide coupling.
• Nanoparticle binding, uptake, and cytotoxicity were evaluated on CD44v6-overexpressing cells loaded with the drug MG2477.

Main Results:

• Conjugated nanoparticles demonstrated specific binding and uptake in cells overexpressing the CD44v6 receptor.
• Drug-loaded nanoparticles significantly increased cytotoxicity compared to the free drug formulation.
• Both anti-CD44v6 antibody and HA targeting strategies showed comparable effectiveness in optimized formulations.

Conclusions:

• PEGylated ORMOSIL nanoparticles are effective nanovectors for targeted cancer therapy.
• Targeting CSCs via CD44v6 receptor using anti-CD44v6 antibodies or HA enhances drug delivery and therapeutic efficacy.
• These targeted nanoparticles represent a promising approach for improving cancer treatment outcomes.